Novavax Stock News

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

Novavax (NASDAQ: NVAX ) stock is taking off on Thursday after the company reached a settlement with global vaccine organization Gavi. This settlement has Novavax agreeing to pay up to $475 million to

The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.

Novavax is making progress along the path to recovery -- and its combined COVID/flu vaccine candidate could drive growth. Pfizer offers better growth prospects than you might think, as well as a juicy

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had creat

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biote

GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fou

After commercializing its first vaccine, Novavax is sputtering as it looks for a follow-up. Its pipeline is looking very thin, and it's being forced to scale down its operations.

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discover

Toast is growing revenue and payment volume in the double digits. Chewy is expanding into Canada, which could become a significant market for the e-commerce company.

Novavax stock surely made millionaires in the past as it rose more than 2,700% back in 2020. Today, the stock has fallen more than 90% from its peak as the company faces various challenges.

Biotechnology firm Novavax (NASDAQ: NVAX )– which specializes in developing and commercializing next-generation vaccines — just announced a fresh round of job cuts. Earlier today, management said

Vaccine maker Novavax said on Wednesday it will reduce its total global workforce by about 12% as part of its ongoing efforts to reduce costs.

Novavax's coronavirus vaccine may be more effective than others. But there isn't much demand anymore, and the biotech's overhead is high.

Novavax shares soared earlier in the pandemic, but they've dropped 98% from their peak. The company faces challenges, but it still could win over time in the post-pandemic vaccine market.